Basic page
Antibodies are among the most widely used affinity reagents to detect or isolate specific molecules. The quality of biomedical research and its findings are highly affected by the quality of the reagents used in the experimental settings.
Our scientists in the Antibody Characterization Laboratory characterize reagent specificity and…
Program
The Cancer Immunoprevention Laboratory develops and tests novel cancer preventive agents, including vaccines, chemoprevention agents, and small molecules, in mouse models in collaboration with several extramural institutions under the sponsorship of the National Cancer Institute. The laboratory is helping develop vaccines to prevent the onset of…
The Cancer Immunoprevention Laboratory focuses on the development and preclinical evaluation of new cancer prevention vaccines and other treatments.
The laboratory evaluates the immunogenicity of novel vaccines targeted to prevent a variety of cancers including cervical, colorectal, prostate, and several solid tumors.
The team collaborates…
Program
The Vaccine, Immunity, and Cancer Directorate conducts preclinical and clinical research in the areas of vaccines, infections and cancer, with an emphasis on human papillomavirus (HPV) and SARS-CoV-2. We develop standards and assays that we validate and use in clinical studies to advance the understanding of immune responses to infection and…
The program helps inform public health decisions by providing data and analysis of antibody responses in a variety of clinical trials. Our translational science is focused on critical health concerns including cancer, HPV, and COVID-19.
Our teams evaluate and validate serology assays and provide scientific and laboratory support for the…
News
As the Frederick National Laboratory for Cancer Research (FNL) expands its serology efforts in response to the COVID-19 pandemic, the biomedical research institution formed a new section dedicated to those efforts and the evaluation and standardization of immune responses to vaccines, infections and cancer.
Establishment of the Vaccine,…
News
A unique library of small-molecule fragments designed and developed by the National Cancer Institute’s RAS Initiative at the Frederick National Laboratory is now furthering the search for a COVID-19 treatment.
Scientist Marcin Dyba holds a tray of compound fragments from the RAS Initiative's tethering library before loading it into the…
News
Scientists at the Frederick National Laboratory for Cancer Research and investigators across the National Institutes of Health (NIH) have developed a highly specific serology test to determine whether a person has antibodies to SARS-CoV-2, a vital tool to understanding the spread of infection from the virus that causes COVID-19.
The…
News
In its urgent efforts to confront the novel coronavirus, the U.S. Food and Drug Administration (FDA) has tapped the Frederick National Laboratory for Cancer Research (FNL) to scientifically inform its decision-making on potential approval of blood tests for the presence of antibodies to SARS-CoV-2.
FNL has an adaptive cancer research…
News
A new international initiative, led by scientists at the Frederick National Laboratory for Cancer Research and several other institutions, is being launched to provide expertise and leadership on the development, validation, and standardization of human papillomavirus (HPV) serology assays to be used in vaccine trials. HPV serology assays measure…
